Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
infusion
every 2 to 4 weeks |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
IgG4
|
| gptkbp:clinicalTrials |
Phase 3 trials
ongoing studies ASCO guidelines adjuvant therapy Phase 1 trials Phase 2 trials NCCN_guidelines neoadjuvant_therapy |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
hepatitis
autoimmune diseases hypersensitivity pneumonitis colitis endocrinopathies |
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
immunosuppressants
live vaccines |
| gptkbp:hasPopulation |
adults
pediatric patients |
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Opdivo
|
| gptkbp:is_monitored_by |
liver function tests
thyroid function tests immune-related side effects |
| gptkbp:lastProduced |
2014
|
| gptkbp:mandates |
gptkb:melanoma
renal cell carcinoma non-small cell lung cancer head and neck cancer |
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketedAs |
nivolumab
|
| gptkbp:merchandise |
billions of dollars
|
| gptkbp:offers |
high
|
| gptkbp:patentStatus |
patented
|
| gptkbp:providesGuidelinesFor |
monitoring during infusion
trained healthcare professional |
| gptkbp:research |
government grants
pharmaceutical companies |
| gptkbp:researchAreas |
biomarkers
immuno-oncology combination therapies |
| gptkbp:route |
intravenous
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
diarrhea rash immune-related adverse events |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
PD-1
|
| gptkbp:triggerType |
inhibits PD-1 receptor
|
| gptkbp:usedFor |
treatment of cancer
|
| gptkbp:variant |
chemotherapy
ipilimumab |